Results 121 to 130 of about 4,782 (272)

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source

Single-versus multiple-inhaler triple therapy in patients with COPD in Spain: a retrospective cohort study comparing adherence, persistence, risk of exacerbations and economic outcomes

Frontiers in Pharmacology
This retrospective study aimed to compare the clinical and economic outcomes of single-inhaler triple therapy (SITT) versus multiple-inhaler triple therapy (MITT) in a large cohort of COPD patients.
M. Asunción González-González, M. Aránzazu Pedrosa-Naudín, Diego Fernández-Lázaro, Isabel Díaz Planelles, F. Javier Álvarez, F. Javier Álvarez, F. Javier Álvarez, Eduardo Gutiérrez-Abejón, Eduardo Gutiérrez-Abejón, Eduardo Gutiérrez-Abejón, Eduardo Gutiérrez-Abejón, Eduardo Gutiérrez-Abejón   +11 more
doaj   +1 more source

Elimination Profile of Deflazacort and Metabolites in Urine and Plasma Following Oral Administration: Relevance to Sports Drug Testing

Drug Testing and Analysis, EarlyView.
Results confirm that the MRL of 30 ng/mL for 21‐desacetyl‐deflazacort together with a 3‐day washout period is an appropriated strategy to detect oral deflazacort administration in sport competition. ABSTRACT Deflazacort (DEF) is a glucocorticoid prohibited in sports competitions when orally administered.
Sergi Coll, Claudia Bressan, Núria Monfort, Ana Aldea‐Perona, Marcel·lí Carbó, Rosa Ventura   +5 more
wiley   +1 more source

Modeled reductions in COPD exacerbation rates, mortality, and related medical costs due to increased SITT adoption: PROMETHEUS Italy

Respiratory Research
Introduction COPD is a leading cause of death and significant healthcare burden in Italy. The ETHOS (NCT02465567||5/2015) and IMPACT (NCT02164513||6/2014) randomized controlled trials (RCTs) have evaluated single-inhaler triple therapy (SITT) and have ...
Pierachille Santus, Bianca Oresta, Davide Finocchiaro, Piergiuseppe De Rosa, John Bell, Melissa Caplen, Jennifer Carioto, Prachi Bhatt, Bruce Pyenson, Alberto Papi   +9 more
doaj   +1 more source

Effectiveness and Safety of Glycopyrronium–Formoterol–Budesonide Triple Therapy in Chronic Obstructive Pulmonary Disease (AIR-FORCE): An Open-Label Multi-Centric Phase 4 Study

Advances in Respiratory Medicine
Chronic obstructive pulmonary disease (COPD) is a major health burden in India with limited real-world data on triple inhaler therapy. This prospective, open-label, multi-center, single-arm, phase 4 study (October 2023–August 2024) assessed the ...
Anjali R. Nath, Adesh Kumar, Amit Suresh Bhate, Bharat Mehrotra, Deependra Kumar Rai, Vijay Kumar Barge, Divya Bhojwani, Sagar Bhagat, Sumit Bhushan, Saiprasad Patil, Hanmant Barkate   +10 more
doaj   +1 more source

Triple therapy for COPD: a crude analysis from a systematic review of the evidence

Therapeutic Advances in Respiratory Disease, 2019
We systematically reviewed the current knowledge on fixed-dose triple therapies for the treatment of chronic obstructive pulmonary disease (COPD), with a specific focus on its efficacy versus single bronchodilation, double fixed dose combinations, and ...
Jose Luis Lopez-Campos, Laura Carrasco-Hernandez, Esther Quintana-Gallego, Carmen Calero-Acuña, Eduardo Márquez-Martín, Francisco Ortega-Ruiz, Joan B. Soriano   +6 more
doaj   +1 more source

Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy

Epilepsia, EarlyView.
Abstract Objective Current pharmacotherapy for temporal lobe epilepsy (TLE) is limited to symptomatic treatment and leaves approximately one third of patients with inadequate seizure control. Discovering disease‐modifying targets is an unmet clinical need. We have previously identified senescent cells (SCs) as one such target. Many drugs that eliminate
David J. McFall, Abbas I. Hussain, Michelle Cho, Patrick A. Forcelli   +3 more
wiley   +1 more source

Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany

International Journal of COPD
Kai-Michael Beeh,1 Kieran J Rothnie,2 Jing Claussen,3 Fränce Hardtstock,4 Rachel K Knapp,4 Thomas Wilke,5 Alexandrosz Czira,2 Chris Compton,6 Afisi S Ismaila7,8 1Insaf Respiratory Research Institute, Wiesbaden, Germany; 2Value Evidence and Outcomes, R&D ...
Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS   +8 more
doaj  

Switching from multiple-inhaler triple therapy to single, extra fine-inhaler triple therapy in severe refractory asthma with EGPA: beyond control. Case report and review of the literature

Drugs in Context
Eosinophilic granulomatosis with polyangiitis is a rare systemic vasculitis associated with asthma, eosinophilia and multi-organ involvement. This case report describes a 69-year-old male with severe, poorly controlled asthma who was diagnosed with ...
Francesco Menzella, Marcello Cottini, Silvia Tonin, Lorenzo Corsi, Annamaria Bosi, Andrea Ballarin, Ariel Floriani, Cristina Dartora, Matteo Tacconi, Carlo Lombardi   +9 more
doaj   +1 more source

Respiratory Syncytial Virus Under the Lens of Structure: From Prefusion Stabilization to Next‐Generation Immunotherapies

iNew Medicine, EarlyView.
This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng, Qianqian Wang, Jiachen Zhang, Sandra Chiu   +3 more
wiley   +1 more source